Integrated Filing — IndAS



General information about company

Scrip Code 544293
NSE Symbol SURAKSHA
MSEI Symbol NOTLISTED
ISIN INE877V01027
Name of company SURAKSHA DIAGNOSTIC LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 10-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 05-11-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment DIAGNOSTIC
Start date and time of board meeting 10-11-2026   15:00:00
End date and time of board meeting 10-11-2026   15:40:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 05-02-2026
Indicate Company website link for updated RPT policy of the Company https://www.surakshanet.com/pdf/investor/Related%20Party%20Transaction%20Policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
“The Company has not defaulted on any of its loan obligations. Further, the disclosure relating to debt securities is not applicable to the Company.”



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 9,453.19 17,861.81
Other income 196.98 353.39
Total income 9,650.17 18,215.20
2 Expenses
(a) Cost of materials consumed 1,049.41 2,020.57
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 1,441.34 2,826.60
(e) Finance costs 478.67 845.67
(f) Depreciation, depletion and amortisation expense 1,188.48 2,248.57
(f) Other Expenses
1 Impairment Loss (2.23) 73.73
2 Advertisement 151.37 209.89
3 Rent Expenses 157.43 292.61
4 Power and fuel 312.13 563.08
5 Professional fees paid 1,504.12 2,890.80
6 Repairs and maintenance 259.69 434.82
7 Information technology expenses 149.75 298.33
8 Security and housekeeping charges 280.98 513.12
9 Commission to collection centre 231.12 410.58
10 Other Expenses 529.72 1,047.40
Total other expenses 3,574.08 6,734.36
Total expenses 7,731.98 14,675.77
3 Total profit before exceptional items and tax 1,918.19 3,539.43
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,918.19 3,539.43
6 Tax expense
7 Current tax 461.39 880.70
8 Deferred tax (73.18) (129.45)
9 Total tax expenses 388.21 751.25
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,529.98 2,788.18
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,529.98 2,788.18
17 Other comprehensive income net of taxes (22.70) (8.46)
18 Total Comprehensive Income for the period 1,507.28 2,779.72
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,041.62 1,041.62
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.93 5.35
Diluted earnings (loss) per share from continuing operations 2.93 5.35
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.93 5.35
Diluted earnings (loss) per share from continuing and discontinued operations 2.93 5.35
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to the unaudited standalone financial results 1. The unaudited standalone financial results for the quarter and year-to -date ended 30 September 2026 (“the financial results”) of Suraksha Diagnostic Limited (“the Company”) have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Regulations”) 2. These unaudited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 10th November 2026. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion. 3. The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 –‘Operating Segments’. 4. These unaudited standalone financial results are also available on the Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseinda.com). 5. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period’s/ year's classification.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 21,490.52
Capital work-in-progress 1,655.69
Investment property 0.00
Goodwill 0.00
Other intangible assets 13,269.04
Intangible assets under development 191.64
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 680.81
Trade receivables, non-current 0.00
Loans, non-current 3,053.26
Other non-current financial assets
1 Other non-current financial assets 4,905.50
Total of other non-current financial assets 4,905.50
Total non-current financial assets 8,639.57
Deferred tax assets (net) 0.00
Other non-current assets
1 Other non-current tax assets (Net) 217.34
2 Other non-current assets 781.08
Total of other non-current assets 998.42
Total non-current assets 46,244.88
2 Current assets
Inventories 943.82
Current financial asset
Current investments 0.00
Trade receivables, current 2,403.19
Cash and cash equivalents 447.64
Bank balance other than cash and cash equivalents 1,053.26
Loans, current 0.00
Other current financial assets
Total of other current financial assets 91.52
Total current financial assets 3,995.61
Current tax assets (net) 0.00
Other current assets
1 Other current assets 585.25
Total of other current assets 585.25
Total current assets 5,524.68
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 51,769.56
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,041.62
Other equity 26,734.12
Total equity attributable to owners of parent 27,775.74
Non controlling interest
Total equity 27,775.74
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 448.46
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 13,188.53
2 Other Financial Liabilities 1,384.21
Total of other non-current financial liabilities 14,572.74
Total non-current financial liabilities 15,021.20
Provisions, non-current 92.12
Deferred tax liabilities (net) 674.41
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 0.00
Total of other non-current liabilities 0.00
Total non-current liabilities 15,787.73
Current liabilities
Current financial liabilities
Borrowings, current 191.48
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 266.36
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,945.51
Total Trade payable 2,211.87
Other current financial liabilities
1 Lease Liabilities 1,459.47
2 Other current financial liabilities 3,909.55
Total of other current financial liabilities 5,369.02
Total current financial liabilities 7,772.37
Other current liabilities 414.76
1 Other current liabilities 414.76
Total of other current liabilities 414.76
Provisions, current 18.96
Current tax liabilities (Net) 0.00
Deferred government grants, Current 0.00
Total current liabilities 8,206.09
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 23,993.82
Total equity and liabilites 51,769.56
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) Notes to the unaudited standalone financial results 1. The unaudited standalone financial results for the quarter and year-to -date ended 30 September 2026 (“the financial results”) of Suraksha Diagnostic Limited (“the Company”) have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Regulations”) 2. These unaudited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 10th November 2026. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion. 3. The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 –‘Operating Segments’. 4. These unaudited standalone financial results are also available on the Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseinda.com). 5. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period’s/ year's classification.



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement gain/(loss) of net defined benefit plan (30.33) (11.31)
2 Income tax effect on above 7.63 2.85
Total Amount of items that will not be reclassified to profit and loss (22.70) (8.46)
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (22.70) (8.46)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3,539.43
Adjustments for reconcile profit (loss)
Adjustments for finance costs 845.67
Adjustments for decrease (increase) in inventories (132.26)
Adjustments for decrease (increase) in trade receivables, current 86.61
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (87.29)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (95.46)
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 347.39
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 130.05
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 2,248.57
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 73.73
Adjustments for provisions, current (52.91)
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current (0.51)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 243.52
Adjustments for share-based payments 16.35
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (91.60)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 3,044.82
Net cash flows from (used in) operations 6,584.25
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 679.31
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 5,904.94
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 60.01
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 244.91
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 16.39
Purchase of property, plant and equipment 3,130.24
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received (180.92)
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (1,195.89)
Net cash flows from (used in) investing activities (4,795.58)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 575.45
Repayments of borrowings 101.69
Payments of lease liabilities 1,359.60
Dividends paid 0.00
Interest paid 6.33
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (892.17)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 217.19
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 217.19
Cash and cash equivalents cash flow statement at beginning of period 230.45
Cash and cash equivalents cash flow statement at end of period 447.64





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Suraksha Diagnostic Limited Suraksha Diagnostic & Eye Centre Private Limited Enterprises owned or significantly influenced by KMP Sale of goods or services 180.00 NA 169.61 77.22 180.53
2 Suraksha Diagnostic Limited Asian Institute of Immunology and Rheumatology LLP Subsidiary of the Company Sale of goods or services 300.00 NA 106.96 242.84 97.55
3 Suraksha Diagnostic Limited Suraksha Salvia LLP Subsidiary of the Company Sale of goods or services 100.00 NA 0.00 52.45 52.45
4 Suraksha Diagnostic Limited Sahayta Clinic LLP Enterprises owned or significantly influenced by KMP Sale of goods or services 5.00 NA 2.27 0.02 0.05
5 Suraksha Diagnostic Limited R.A. Enterprises Enterprises owned or significantly influenced by KMP Purchase of goods or services 1,250.00 NA 1,078.30 178.31 127.80
6 Suraksha Diagnostic Limited Kejriwal Electronics Limited Enterprises owned or significantly influenced by KMP Purchase of goods or services 10.00 NA 1.63 0.48 0.00
7 Suraksha Diagnostic Limited Oscar Enclave Private Limited Enterprises owned or significantly influenced by KMP Any other transaction Rent Expenses 1,830.99 NA 241.41 34.95 38.14
8 Suraksha Diagnostic Limited Kejriwal Constructions Enterprises owned or significantly influenced by KMP Any other transaction Rent Expenses 188.02 NA 34.21 5.22 5.22
9 Suraksha Diagnostic Limited Suresh Enterprise Enterprises owned or significantly influenced by KMP Any other transaction Rent Expenses 151.76 NA 17.13 2.61 2.61
10 Suraksha Diagnostic Limited Raghavi Mittal Relative of KMP Remuneration 5.00 NA 0.00 0.45 0.00
11 Suraksha Diagnostic Limited Aparajita Chatterjee Relative of KMP Any other transaction Professional fee 15.00 NA 12.76 1.81 1.82
12 Suraksha Diagnostic Limited Tandra Chatterjee Relative of KMP Any other transaction Professional fee 1.50 NA 0.44 0.08 0.03
13 Suraksha Diagnostic Limited Sahayta Clinic LLP Enterprises owned or significantly influenced by KMP Any other transaction Commission paid 5.00 NA 0.55 0.22 0.31
14 Suraksha Diagnostic Limited Suraksha Speciality LLP Subsidiary of the Company Interest received 0.00 NA 3.68 0.00 0.00
15 Suraksha Diagnostic Limited Asian Institute of Immunology and Rheumatology LLP Subsidiary of the Company Interest received 0.00 NA 4.91 0.00 0.00
16 Suraksha Diagnostic Limited Suraksha Radiology Private Limited Subsidiary of the Company Interest received 0.00 NA 42.80 0.00 0.00
17 Suraksha Diagnostic Limited Asian Institute of Immunology and Rheumatology LLP Subsidiary of the Company Loan 0.00 NA 200.00 0.17 204.42
18 Suraksha Diagnostic Limited Suraksha Radiology Private Limited Subsidiary of the Company Loan 0.00 NA 0.00 1,211.49 1,250.01
19 Suraksha Diagnostic Limited Suraksha Speciality LLP Subsidiary of the Company Loan 0.00 NA 2.00 242.47 254.79
20 Suraksha Diagnostic Limited Suraksha Speciality LLP Subsidiary of the Company Advance 0.00 NA 7.00 3.19 3.19
21 Suraksha Diagnostic Limited Asian Institute of Immunology and Rheumatology LLP Subsidiary of the Company Advance 0.00 NA 0.00 0.06 0.06
22 Suraksha Diagnostic Limited Suraksha Radiology Private Limited Subsidiary of the Company Advance 0.00 NA 10.06 36.92 46.97
23 Suraksha Diagnostic Limited Suraksha Salvia LLP Subsidiary of the Company Advance 0.00 NA 0.00 40.26 40.26
24 Suraksha Diagnostic Limited Ritu Mittal Key Managerial Personnel Remuneration 0.00 NA 108.00 11.45 11.45
25 Suraksha Diagnostic Limited Somnath Chatterjee Key Managerial Personnel Remuneration 0.00 NA 108.00 11.45 11.45
26 Suraksha Diagnostic Limited Asian Institute of Immunology and Rheumatology LLP Subsidiary of the Company Investment 0.00 NA 60.00 120.00 180.00
27 Suraksha Diagnostic Limited Suraksha Speciality LLP Subsidiary of the Company Investment 0.00 NA 0.00 50.00 50.00
28 Suraksha Diagnostic Limited Suraksha Radiology Private Limited Subsidiary of the Company Investment 0.00 NA 0.00 0.74 0.74
29 Suraksha Diagnostic Limited Oscar Enclave Private Limited Enterprises owned or significantly influenced by KMP Any other transaction Security deposit given 0.00 NA 0.00 114.60 114.60
30 Suraksha Diagnostic Limited Suresh Enterprise Enterprises owned or significantly influenced by KMP Any other transaction Security deposit given 0.00 NA 0.00 12.00 12.00
31 Suraksha Diagnostic Limited Suraksha Advance Radiology Private Limited Subsidiary of the Company Advance 0.00 NA 11.51 4.16 15.67
32 Suraksha Diagnostic Limited Suraksha Advance Radiology Private Limited Subsidiary of the Company Investment 0.00 NA 0.00 0.74 0.74
33 Suraksha Diagnostic Limited Suraksha Advance Radiology Private Limited Subsidiary of the Company Interest received 0.00 NA 57.88 0.00 0.00
34 Suraksha Diagnostic Limited Suraksha Advance Radiology Private Limited Subsidiary of the Company Loan 0.00 NA 47.00 1,303.04 1,402.13
35 Suraksha Diagnostic Limited Asian Institute of Immunology and Rheumatology LLP Subsidiary of the Company Any other transaction Service Charges / Technical Fees 75.00 NA 12.42 37.81 0.00
36 Suraksha Diagnostic Limited Fetomat Wellness Private Limited Subsidiary of the Company Sale of goods or services 100.00 NA 33.97 4.94 4.39
37 Suraksha Diagnostic Limited Fetomat Wellness Private Limited Subsidiary of the Company Any other transaction Service Charges / Technical Fees 0.00 NA 4.31 0.41 0.55
38 Suraksha Diagnostic Limited Fetomat Wellness Private Limited Subsidiary of the Company Investment 0.00 NA 0.00 459.63 459.63
39 Suraksha Diagnostic Limited Rahat Mittal Relative of KMP Any other transaction Professional fee 6.00 NA 6.00 0.90 0.90
40 Suraksha Diagnostic Limited Tathagata Chatterjee Relative of KMP Any other transaction Professional fee 1.50 NA 0.44 0.08 0.07
41 Suraksha Diagnostic Limited Oscar Enclave Private Limited Enterprises owned or significantly influenced by KMP Any other transaction Reimbursement of Electricity Expenses 0.00 NA 5.16 0.00 0.00
42 Suraksha Diagnostic Limited Surjyamukhi Bhattacharyya Relative of KMP Any other transaction Professional fee 1.50 NA 0.56 0.00 0.16
Total value of transaction during the reporting period 2,390.97